Brintellix (vortioxetine) is applied in addressing the symptoms of Major Depressive Disorder (MDD) in adult patients. Its use is centered on addressing a broad range of symptomatic domains associated with this condition, and may assist with maintaining functional stability and supports patients during difficult episodes.

Brintellix is used to treat major depression in adults, a condition where symptoms interfere with daily functioning.

---

The treatment is commonly used across conditions characterized by recurrent major depressive episodes. It is applied in addressing the primary manifestations of depression, including persistent sadness and profound loss of interest or pleasure. The treatment provides assistance in managing cognitive dysfunction, which involves difficulties with concentration and mental processing.

“The treatment contributes to easing the overall symptom load, particularly in managing the cognitive and executive symptoms often seen alongside mood disturbances.”

---

Quick Fact: Support for Cognitive Symptoms

Focus	Symptom Category	Benefit
Primary Indication	Major Depressive Disorder (MDD)	Assists with mood management
Symptom Domain	Cognitive and Executive	May help manage symptoms that interfere with concentration
Context of Use	Acute & Maintenance Phases	Is relevant for managing symptoms that interfere with daily comfort

---

It is commonly used during the maintenance phase to help manage symptom fluctuations, providing supportive relief when symptoms interfere with routine activities, which is relevant in situations involving recurrent or episodic manifestations.

Regulatory References

1. Brintellix (Vortioxetine) EPAR Overview

Official Eligibility Rules for Vortioxetine

The eligibility for using vortioxetine is strictly defined by regulatory authorities based on age, concurrent medications, and specific medical conditions.

Category	Regulatory Status
Approved Population	Adult patients (aged 18 and older) are the officially indicated population.
Contraindicated Populations	Patients with known hypersensitivity to vortioxetine or any component. Patients currently taking Monoamine Oxidase Inhibitors (MAOIs) or who have stopped an MAOI in the last 14 days. This includes drugs like Linezolid or Intravenous Methylene Blue.
Pediatric Use (<18)	Not recommended for use in pediatric patients as efficacy and safety have not been established by regulatory bodies.
Geriatric Use (ge 65)	Use is permitted, but official labeling advises caution with doses higher than 10 mg/day.
Severe Organ Impairment	Use is not recommended in patients with Severe Hepatic Impairment. No dose adjustment is needed for any stage of renal impairment or for mild/moderate hepatic impairment.
Pregnancy/Lactation	Use in pregnancy is conditional; third-trimester exposure may increase the risk of neonatal complications. Vortioxetine is present in breast milk.

The official labeling also advises caution in patients with a history of mania/hypomania or seizures, defining conditional use based on these specific comorbidities.

The official interaction profile for Brintellix (vortioxetine) is defined by mandatory restrictions related to the serotonergic system and formal requirements for managing pharmacokinetic exposure via the CYP2D6 metabolic pathway.

Interaction Entity	Regulatory Status & Requirement
Contraindicated Combinations	Prohibited with Monoamine Oxidase Inhibitors (MAOIs) intended for psychiatric disorders, including Linezolid and Intravenous Methylene Blue.
Timing-Separation Rules	A minimum 14-day washout is required between discontinuing an MAOI and initiating vortioxetine, and 21 days between discontinuing vortioxetine and initiating an MAOI.

Official Interaction Statements

• Pharmacokinetic Interactions: Vortioxetine is primarily metabolized by CYP2D6. Co-administration with strong CYP2D6 inhibitors (e.g., Bupropion, Fluoxetine) significantly increases vortioxetine exposure, necessitating a mandated dose reduction. Strong CYP inducers (e.g., Rifampin) decrease exposure, requiring consideration of a dose increase.
• Pharmacodynamic Interactions: Co-administration with other serotonergic agents (e.g., Triptans, Tramadol, St. John's Wort) poses a documented risk of Serotonin Syndrome (SS).
• Bleeding Risk: Co-administration with Anticoagulants (e.g., Warfarin) and Antiplatelet Agents (e.g., NSAIDs, Aspirin) increases the regulatory documented risk of abnormal bleeding.
• Administration Status: The medication may be taken without regard to food, and no restrictions exist for clinically meaningful transporter interactions.

Core: Multimodal Serotonin Transporter and Receptor Engagement

The drug vortioxetine initiates its biological action by simultaneously acting on the Serotonin Transporter ( SERT) and multiple serotonin receptors (including 5-HT1A, 5-HT3, and 5-HT7). It functions as an Inhibitor of the SERT and a direct Modulator (agonist/antagonist) of these receptors. This dual-action approach modulates the serotonergic system through multiple interactions with receptors and the transporter.

---

Cascading Effect: Multisystem Neurotransmitter Alteration

By directly modulating receptors like the 5-HT3 receptor (an Antagonist action), the drug indirectly influences the release of other critical chemical messengers, specifically Dopamine, Norepinephrine, and Glutamate. This process of disinhibition (removing a regulatory brake) initiates a multisystem cascade that alters the signaling of multiple neurotransmitters in key brain areas.

---

Physiological Result: Neural Circuit Regulation

The synchronous alteration of Serotonin, Dopamine, and Norepinephrine signaling affects the regulation of central nervous system neural circuits. Furthermore, the drug’s specific receptor modulation influences the rate of functional adaptation within these pathways, which collectively shape the resulting physiological changes.

Official Administration Guidelines for Vortioxetine

The general principle for using vortioxetine (Brintellix) is based on a standardized, once-daily oral schedule that is independent of food intake. The medicine is provided as immediate-release film-coated tablets in strengths of 5 mg, 10 mg, 15 mg, and 20 mg, and must be swallowed whole.

Standard Dosing and Adjustments

For adults under 65, the administration protocol typically starts with a dose of 10 mg once daily. The standard maintenance dose range is established between 5 mg and a maximum recommended daily dose of 20 mg, with adjustments guided by individual response. The medicine should be taken at approximately the same time each day to maintain procedural consistency.

Specific guidelines apply to certain contexts: for older adults (65 years and over), the lowest effective dose of 5 mg once daily is recommended. Dosing also requires modification when used with specific co-medications; for instance, the vortioxetine dose must be reduced by one-half when co-administered with a strong CYP2D6 inhibitor. If a dose is missed, the next scheduled dose is taken at the usual time and the missed dose is not taken.

Treatment Duration and Discontinuation

For long-term usage, therapy is typically continued for at least 6 months after symptom resolution to consolidate the treatment response. Discontinuation of the higher doses (15 mg or 20 mg) involves a planned taper, requiring the dose to be reduced to 10 mg/day for one week before the medicine is fully stopped.

Evidence for the Acute and Maintenance Treatment of Major Depressive Disorder (MDD)

Research examining vortioxetine was evaluated in short-term, randomized, double-blind, placebo-controlled trials (RCTs). These studies explored how symptoms change over time in adults with Major Depressive Disorder (MDD), monitoring changes in the overall intensity of depressive symptoms using standardized scales. Studies conducted during periods of increased symptom activity described the observed symptom patterns in the populations compared to a placebo.

Further research examined the potential for sustained observation, utilizing randomized withdrawal studies that described patterns of time until the recurrence or relapse of depressive episodes. These randomized designs were used to monitor symptom patterns over defined time intervals in patients who had already reached a stage of stability. The core findings were derived from these short-term acute trials.

Research Focus on Cognitive Dysfunction Associated with MDD

Research was studied for cognitive outcomes, such as attention and processing speed, in populations with MDD. These studies focused on episodes where symptoms become more noticeable and used objective neuropsychological tests to measure specific cognitive performance. Findings contribute to understanding symptom patterns related to measured performance on these tests. Some trial reports described patterns where changes in objective cognitive scores were observed in some studies regardless of overall changes in depressive mood symptoms.

Long-Term Data and Uncertainties

The research landscape includes long-term extension studies, though high-certainty placebo-controlled data is primarily from short-term acute trials. Long-term effects are not fully established using high-certainty methods. Specific research was evaluated in older adults (aged 65 and over), and subgroup analyses were studied for patients with high anxiety symptoms. However, results apply only to the populations studied, and data for certain groups, such as children, remain insufficient within the regulatory evidence record. Comparative evidence is lacking when assessing outcomes against every other established antidepressant class.

Common questions about Бринтелликс (FAQ)

Q: Can I take this medication with alcohol?

A: Official product information addresses the risks associated with consuming alcohol while taking this medication. Regulatory documents caution that combining the two may increase certain side effects, such as drowsiness or dizziness. Specific advice on this interaction can be found in the full regulatory document.

Q: Does this drug cause weight gain or loss?

A: Changes in body weight, which may include either weight gain or weight loss, have been reported among the adverse reactions listed in the official drug labeling. This is noted in the Adverse Reactions section of the regulatory documents. Details regarding the reported frequency of these changes are also found in the official labeling.

Q: How should I store this medicine?

A: Regulatory documents specify the correct storage conditions to maintain the medication's effectiveness and stability. Typically, the medicine should be stored at room temperature and protected from excessive moisture and heat. The exact storage temperature range and handling precautions are detailed in the official regulatory labeling (e.g., FDA Label Section 16).

Q: Is it safe to take this drug if I am pregnant or breastfeeding?

A: The official product information contains specific statements regarding the use of this medication during pregnancy and while breastfeeding. These statements are based on available human and/or animal data related to potential risks. Specific details concerning use during pregnancy and lactation are addressed in the 'Use in Specific Populations' section of the regulatory documentation.

Q: Can I stop taking this drug once my symptoms improve?

A: Instructions for the administration and cessation of treatment are included in the official labeling. These instructions often cover the recommended duration of therapy and may include advice on gradually stopping the medication to reduce the risk of symptom recurrence or withdrawal effects. The guidance established in the regulatory documents should be referenced regarding continuation or discontinuation of the medication.

Q: Is this drug safe for children and teenagers?

A: Official information explicitly states the approved age range for the use of this medication, which is found under the 'Pediatric Use' section of the regulatory documentation. If the medication is not authorized for pediatric use, regulatory documents generally state that the safety and efficacy in this population have not been established.

Q: Is it safe to use this medication for many years (long-term safety)?

A: The official documentation addresses the risks and precautions associated with the prolonged or long-term administration of the medication. This includes detailing potential risks and noting any monitoring considerations relevant to extended treatment periods. This information is typically found within the 'Warnings and Precautions' section.

How to Store and Dispose of Brintellix (Vortioxetine)

Brintellix film-coated tablets must be stored at controlled room temperature, maintaining a range between 15 C and 30 C (59 F and 86 F). The medicine must be protected from heat, moisture, direct light, and freezing to ensure stability. It should be kept in a closed container and stored out of the sight and reach of children as specified in the official labeling.

For disposal, unused or outdated medicine should not be kept. Patients are instructed to consult a pharmacist or healthcare professional for guidance on the proper procedure to discard the medicine, ensuring compliance with local pharmaceutical waste regulations.